External Magnetic Control
External magnets or robotic magnetic systems steer the capsule through the stomach for more deliberate mucosal inspection.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Magnetically Controlled Capsule Gastroscopy, Mechanically / Tether Controlled Capsule Gastroscopy), By Application (Specialized Hospital, General Hospital, Others), By End User (Hospitals, Gastroenterology & Diagnostic Centers, Academic & Research Institutions), By Control Mode (External Magnetic Navigation, Tether-Assisted Navigation, Passive / Free-Moving Capsule Systems), By Clinical Use (Gastric Screening, Diagnostic Evaluation, Follow-up & Surveillance), and Regional Forecast, 2026-2034
The global in vitro capsule gastroscopy market was valued at USD 380.0 million in 2025 and is estimated at USD 411.5 million in 2026. The market is projected to reach USD 778.8 million by 2034, representing an 8.3% CAGR during 2026–2034.
In vitro capsule gastroscopy uses ingestible camera capsules to visualize gastrointestinal mucosa without conventional flexible gastroscope insertion. The most advanced stomach-focused platforms add external magnetic control or tether-assisted positioning so clinicians can direct capsule movement and improve gastric surface coverage.
Regulatory recognition of magnetically maneuvered capsule systems has strengthened the category. FDA cleared ANX Robotica’s NaviCam stomach capsule systems through multiple 510(k) submissions, including K221608 and a 2024 update under K241934. These systems are regulated as magnetically maneuvered capsule endoscopy devices rather than passive small-bowel-only capsules.
The broader capsule-endoscopy ecosystem also benefits from mature imaging and software infrastructure. Medtronic’s PillCam SB 3 provides adaptive 2–6 frame-per-second imaging and at least eight hours of operation, while ESGE continues to recommend capsule endoscopy as a first-line examination in selected small-bowel indications. Gastric capsule systems extend the patient-friendly concept toward controlled stomach visualization.
Source: FDA NaviCam K241934; FDA NaviCam K221608; FDA NaviCam small bowel K221590; ESGE capsule endoscopy guideline; Medtronic PillCam SB 3.
The study defines the global in vitro capsule gastroscopy market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Magnetically Controlled Capsule Gastroscopy; Mechanically / Tether Controlled Capsule Gastroscopy |
| By Application | Specialized Hospital; General Hospital; Others |
| By End User | Hospitals; Gastroenterology & Diagnostic Centers; Academic & Research Institutions |
| By Control Mode | External Magnetic Navigation; Tether-Assisted Navigation; Passive / Free-Moving Capsule Systems |
| By Clinical Use | Gastric Screening; Diagnostic Evaluation; Follow-up & Surveillance |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; China; Japan; South Korea; Germany; United Kingdom; France; Italy; India; Australia and other relevant markets |
| Key Market Players | ANX Robotica / Ankon Technologies; Medtronic; IntroMedic; Jinshan Science & Technology; CapsoVision; Olympus; MicroPort |
The market includes ingestible capsule systems, navigation hardware and dedicated software used primarily for stomach-focused capsule gastroscopy and controlled gastrointestinal visualization.
Conventional flexible gastroscopes, colonoscopes, unrelated imaging capsules and capsule products used only for drug delivery are outside the core revenue boundary.
The stomach is a relatively large cavity, so active capsule control can improve mucosal coverage compared with purely passive transit. FDA clearance of magnetically maneuvered systems supports this technology pathway.
Capsule procedures avoid conventional scope insertion and sedation in selected use cases, creating value for patients who are reluctant to undergo standard gastroscopy.
Capsule procedures generate large image sequences. Reading time and lesion recognition remain important workflow considerations, strengthening demand for better software and automated image triage.
FDA has cleared multiple NaviCam stomach-system iterations, including K241934, showing continued commercial refinement of magnetically maneuvered capsule technology.
Capsule systems can visualize mucosa but cannot biopsy or treat lesions. Positive findings can therefore require follow-up conventional endoscopy.
Source: FDA K241934; FDA K221608; ESGE.
Active external guidance improves the ability to inspect different gastric regions and reduces dependence on natural capsule transit.
Large image volumes create a clear role for automated triage, lesion highlighting and remote interpretation tools.
Tethered designs can allow repeated inspection and controlled capsule retrieval in selected stomach-focused workflows.
Modern capsules offer high-resolution imaging, adaptive frame rates and long operating times while maintaining very small form factors.
Specialized gastroenterology centers are adopting controlled capsule systems earlier than general facilities because they have the staff and patient volume needed to support interpretation and follow-up.
Source: FDA K241934; Medtronic; ESGE.
Capsule gastroscopy combines miniaturized imaging, wireless data transfer and, in advanced systems, external control of capsule position.
External magnets or robotic magnetic systems steer the capsule through the stomach for more deliberate mucosal inspection.
A tether can support controlled positioning, repeated inspection and retrieval after the examination.
The capsule integrates optics, illumination, battery and wireless communication in an ingestible form factor.
Software organizes thousands of images and can support lesion review, study navigation and remote interpretation.
Source: FDA K221608; FDA K241934; Medtronic.
By type, the market is segmented into magnetically controlled and mechanically or tether controlled capsule gastroscopy. Magnetically controlled systems lead because active external guidance supports systematic stomach examination.
External magnetic guidance allows clinicians to maneuver the capsule through different gastric regions and improve visualization.
Tether-assisted or mechanically controlled systems provide directional control and retrieval without relying only on passive transit.
Magnetic control is expected to remain the leading premium category because stomach examination benefits substantially from active navigation.
By application, the market is segmented into specialized hospitals, general hospitals and other settings. Specialized hospitals lead because controlled capsule gastroscopy requires gastroenterology expertise, dedicated software and access to follow-up endoscopy.
Specialized GI centers manage higher procedure volumes and complex referrals and can integrate capsule findings with conventional endoscopy.
General hospitals are increasingly adopting non-invasive diagnostics where gastroenterology and imaging infrastructure are available.
Other settings include diagnostic centers, research sites and selected screening programs.
Specialized hospitals will remain the largest application, while general hospitals should expand as systems become easier to deploy and interpret.
By end user, the market is segmented into hospitals, gastroenterology and diagnostic centers, and academic or research institutions. Hospitals remain the leading value segment.
Hospitals combine physician access, diagnostic follow-up and reimbursement infrastructure needed for capsule gastroscopy.
Dedicated centers can use capsule systems for high-volume, patient-friendly diagnostic workflows.
Academic centers evaluate navigation, image analysis and new indications and contribute to clinical validation.
Hospitals and gastroenterology centers will account for most commercial demand, while academic institutions continue to drive technology validation.
By control mode, the market is segmented into external magnetic navigation, tether-assisted navigation and passive or free-moving capsule systems. External magnetic navigation leads stomach-focused applications.
Magnetic control enables deliberate examination of the gastric fundus, body, antrum and other regions.
Tethering can allow controlled movement and reinspection while preserving a swallowable capsule form.
Passive systems rely on natural GI motility and are best established in small-bowel imaging rather than full gastric mapping.
External magnetic navigation should capture the strongest stomach-specific value because it addresses the central limitation of passive gastric transit.
By clinical use, the market is segmented into gastric screening, diagnostic evaluation, and follow-up or surveillance. Diagnostic evaluation is the leading current use.
Capsule imaging can investigate symptoms or patients who prefer a non-invasive initial visualization approach.
Non-invasive capsule systems may support selected screening programs where conventional gastroscopy capacity or acceptance is limited.
Repeat capsule imaging may be useful in selected patients when visual monitoring is needed without immediate biopsy or treatment.
Diagnostic evaluation will remain the largest use, while screening creates the strongest long-term volume opportunity if reimbursement and clinical protocols expand.
Regional adoption reflects regulatory clearance, gastroenterology infrastructure and familiarity with capsule endoscopy. North America leads the current market framework, while Asia-Pacific is a major technology-development region.
FDA-cleared magnetically maneuvered systems and strong capsule-endoscopy infrastructure support the leading market position.
European clinical guidance strongly supports capsule endoscopy in selected GI indications, creating a receptive specialist environment.
China is an important development center for magnetically controlled capsule technology, while Japan and South Korea have advanced endoscopy infrastructure.
Adoption is concentrated in private hospitals and major GI centers.
Premium hospitals in Gulf markets lead regional uptake, while broader adoption depends on specialist access and reimbursement.
Source: FDA K241934; ESGE; Medtronic.
Capsule gastroscopy systems are regulated medical devices and require validated imaging, biocompatibility, wireless performance and instructions for safe use.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Magnetically maneuvered device class | FDA identifies NaviCam stomach systems as magnetically maneuvered capsule endoscopy devices under 21 CFR 876.1310. | Establishes a defined regulatory pathway. |
| Multiple device iterations | FDA cleared K221608 and later K241934, showing ongoing system refinement. | Supports commercial maturity. |
| Capsule retention consideration | Capsule endoscopy can be unsuitable where GI obstruction or severe stenosis is suspected. | Keeps patient selection important. |
| Follow-up limitations | Capsules cannot biopsy or perform therapy. | Positive findings may require conventional endoscopy. |
Source: FDA K221608; FDA K241934; ESGE.
The market is led by capsule-endoscopy specialists and larger GI-device companies. Competition centers on navigation, image quality, software, procedure workflow and regulatory access.
NaviCam provides FDA-cleared magnetically maneuvered stomach-capsule systems.
PillCam provides one of the largest installed capsule-endoscopy ecosystems, particularly in small-bowel imaging.
Specialists compete through imaging design, capsule hardware, software and geographic focus.
Source: FDA NaviCam; Medtronic.
August 2026 database update: FDA records continued to list NaviCam Xpress Stomach Capsule Endoscope System under the magnetically maneuvered capsule endoscopy classification.
2024 clearance: FDA cleared an updated NaviCam Xpress Stomach System under K241934.
Current platform cycle: Medtronic continues to support adaptive-frame-rate PillCam capsule technology and cloud-compatible review workflows.
Current clinical environment: ESGE continues to support capsule endoscopy as a first-line examination in selected small-bowel indications, sustaining broader physician familiarity with ingestible imaging.
Source: FDA K241934; Medtronic; ESGE.
The global in vitro capsule gastroscopy market market is projected to grow from USD 411.5 million in 2026 to USD 778.8 million by 2034, at a 8.3% CAGR during 2026–2034. Growth is expected to be supported by magnetic navigation, patient preference for less-invasive examination and improved image-analysis workflows. Specialized hospitals should remain the core commercial setting while more compact and software-driven systems expand access.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Magnetic control | Active steering improves stomach coverage. | Supports premium adoption. |
| Patient comfort | Swallowable imaging avoids conventional scope insertion in selected cases. | Expands acceptance. |
| Software | Image triage and remote reading reduce interpretation burden. | Improves workflow. |
| Regulatory maturity | Multiple FDA clearances validate a defined device class. | Supports commercialization. |
| Hospital expansion | More GI centers are evaluating non-invasive imaging alternatives. | Broadens demand. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global in vitro capsule gastroscopy market landscape.
24LifeScience develops in vitro capsule gastroscopy market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines the defined market scope with current FDA capsule-endoscopy clearances, ESGE clinical guidance and primary manufacturer information. The displayed 2026 and 2034 values reconcile to an 8.3% CAGR.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 380.0 million in 2025 and is estimated at USD 411.5 million in 2026. It is projected to reach USD 778.8 million by 2034 at an 8.3% CAGR during 2026–2034.
Magnetically controlled capsule gastroscopy leads because active navigation improves gastric visualization.
Specialized hospitals lead because they combine capsule expertise with conventional endoscopy for follow-up.
North America leads the current market framework, supported by FDA-cleared magnetically maneuvered systems and advanced GI imaging infrastructure.
It uses an ingestible camera capsule and can avoid scope insertion and sedation in selected cases, but it cannot biopsy or treat lesions.
An external magnetic system steers the capsule within the stomach to improve mucosal coverage.
Reading workload, inability to biopsy or treat, reimbursement and patient-selection requirements remain important limitations.
The report profiles ANX Robotica/Ankon, Medtronic, IntroMedic, Jinshan Science & Technology, CapsoVision and other capsule-endoscopy specialists.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.